Replimune (REPL) Total Non-Current Liabilities (2018 - 2025)
Replimune's (REPL) quarterly Total Non-Current Liabilities came in at $122.4 million in Q4 2025, up 1.98% year-on-year from $120.0 million in Q4 2024, and down 2.25% quarter-over-quarter from $125.2 million in Q3 2025.
Replimune (REPL) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Replimune has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $122.4 million for Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $122.4 million, up 1.98% year-over-year; the trailing twelve-month figure through Dec 2025 was $122.4 million (up 1.98% YoY), and the FY2025 annual result was $134.5 million, up 19.67% from the prior year.
- Total Non-Current Liabilities came in at $122.4 million for Q4 2025 at Replimune, down from $125.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $134.5 million in Q1 2025 to a low of $50.0 million in Q1 2022.
- The 4-year median for Total Non-Current Liabilities is $112.4 million (2024), against an average of $108.3 million.
- Across the five-year window, Total Non-Current Liabilities surged 81.79% in 2023 and gained 1.98% in 2025, its largest moves.
- Replimune's Total Non-Current Liabilities stood at $50.0 million in 2022, then soared by 121.36% to $110.6 million in 2023, then grew by 8.49% to $120.0 million in 2024, then rose by 1.98% to $122.4 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $122.4 million (Q4 2025), $125.2 million (Q3 2025), and $131.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | 122.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 122.36 Mn |
| Sep 30, 2025 | 125.17 Mn |
| Jun 30, 2025 | 131.85 Mn |
| Mar 31, 2025 | 134.54 Mn |
| Dec 31, 2024 | 119.99 Mn |
| Sep 30, 2024 | 115.96 Mn |
| Jun 30, 2024 | 107.73 Mn |
| Mar 31, 2024 | 112.43 Mn |
| Dec 31, 2023 | 110.60 Mn |
| Sep 30, 2023 | 96.75 Mn |
| Jun 30, 2023 | 89.28 Mn |
| Mar 31, 2023 | 90.83 Mn |
| Mar 31, 2022 | 49.96 Mn |
| Mar 31, 2019 | 16.47 Mn |
| Dec 31, 2018 | 8.95 Mn |
| Sep 30, 2018 | 3.78 Mn |
| Jun 30, 2018 | 4.54 Mn |
| Mar 31, 2018 | 5.22 Mn |